Liggins Institute, University of Auckland, Auckland 1142, New Zealand.
National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo 162-8636, Japan.
Nutrients. 2022 Mar 18;14(6):1288. doi: 10.3390/nu14061288.
Nutrition and weight gain during pregnancy can influence the life-course health of offspring. Clinical practice guidelines play an important role in ensuring appropriate nutrition and weight gain among pregnant women. This study aims to identify clinical practice guidelines on gestational weight gain and/or maternal nutrition across the Asia-Pacific region and to determine the quality of the guidelines and variability in the recommendations. Through a systematic search of grey literature from 38 Asia-Pacific countries, 23 published guidelines were obtained. Of these, 10 eligible clinical practice guidelines reporting nutrition- or/and weight-related recommendations for pregnant women were selected and reviewed. Guideline quality was determined using the Assessment of Guidelines for Research Evaluation II (AGREE II) instrument. Of the 10 guidelines, 90% were classified as low-quality in the AGREE II appraisal. Several variations were found with respect to recommendations on gestational weight gain, including those specific to Asian populations. The recommendations on dietary advice, additional energy intake, and nutritional supplementation during pregnancy were varied. Clinical practice guidelines on weight gain and nutrition in pregnancy across the Asia-Pacific region are generally of poor quality, reflecting significant variation, and need to be improved to ensure pregnant women receive appropriate advice. (PROSPERO registration no. CRD42021291395).
孕期营养和体重增加会影响后代的终生健康。临床实践指南在确保孕妇获得适当的营养和体重增加方面发挥着重要作用。本研究旨在确定亚太地区妊娠期体重增加和/或孕产妇营养的临床实践指南,并确定指南的质量和建议的可变性。通过对来自 38 个亚太国家的灰色文献进行系统搜索,获得了 23 份已发表的指南。其中,选择并审查了 10 份符合条件的报告了针对孕妇的营养和/或体重相关建议的临床实践指南。使用评估指南研究评价 II(AGREE II)工具确定指南质量。在 AGREE II 评估中,10 份指南中有 90%被归类为低质量。关于妊娠期体重增加的建议存在一些差异,包括针对亚洲人群的建议。关于膳食建议、额外能量摄入和孕期营养补充的建议存在差异。亚太地区妊娠期体重增加和营养的临床实践指南总体质量较差,反映出显著的差异,需要加以改进,以确保孕妇获得适当的建议。(PROSPERO 注册号:CRD42021291395)。